跳至主要内容
临床试验/NCT03231371
NCT03231371已完成3 期

Early Detection of Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients: A Prospective Assessment Using Coronary Flow Reserve and Contrast-Enhanced Cardiac MRI

Bryan Goldstein1 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2008年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
22
试验地点
1
主要终点
Coronary Flow Reserve (CFR)

研究概览

简要总结

Heart transplantation is a life-sustaining therapy that allows patients with either congenital or acquired heart disease and severe cardiac dysfunction to survive. Over time, however, the transplanted heart can develop problems. One of the more common and troubling problems is the development of stenoses, or narrowings, within the coronary arteries. These narrowings, technically referred to as coronary artery vasculopathy (CAV for short), account for the single most common cause of death or need for repeat heart transplant in persons more than one year post-transplant. Traditionally, CAV has been diagnosed at cardiac catheterization using coronary angiography (where dye is directly injected into the coronary blood vessels and viewed using special x-ray equipment called fluoroscopy). There is no good treatment for CAV aside from treatment of symptoms and listing for repeat heart transplantation. The goal of this study is to test several newer methods of diagnosing CAV. The first is called coronary flow reserve (catheterization test). The second is called Endo-PAT (a finger probe test) and the third is called contrast-enhanced cardiac MRI (MRI test, only for patients 12 and older). The older method (coronary angiography) will still be used in all cases, in addition to the new tests The goal is, one day, to be able to diagnose patients with CAV earlier in the course, prior to a patient's development of abnormal angiograms. If this can be done, it is possible that better therapies will be able to be used to stop or even reverse the development of CAV, perhaps reducing, or at least delaying, the need for repeat heart transplantation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
1 Year 至 25 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Patients age 1 - 25 years who are status-post OHT (≤18 years at the time of transplantation) and undergoing routine post-transplant surveillance catheterization for endomyocardial biopsy and coronary angiography

排除标准

  • The presence of sick sinus syndrome or 2nd or 3rd degree atrioventricular block (without a functioning implanted pacemaker)
  • Hemodynamically significant valvular disease
  • Severe asthma or bronchospasm, known severe CAV
  • Pulmonary hypertension.
  • Patients taking digoxin
  • Verapamil and dipyridamole are also excluded given known interactions with adenosine.

研究组 & 干预措施

Study Arm

Experimental

干预措施: Adenosine (Drug)

结局指标

主要结局

Coronary Flow Reserve (CFR)

时间窗: Baseline testing (acute only), 3 minutes of adenosine infusion

Ratio of peak to baseline coronary flow velocity (CFV)

次要结局

  • Gadolinium Enhancement by Cardiac MRI(Baseline MRI only)

研究者

发起方
Bryan Goldstein
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Bryan Goldstein

Principal Investigator, Clinical Lecturer

University of Michigan

研究点 (1)

Loading locations...

相似试验

Coronary Artery Vasculopathy in Pediatric Heart... | 临床试验